BioXcel Therapeutics, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Wiley Matthew T.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Wiley Matthew T. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:BTAI / BioXcel Therapeutics, Inc. Chief Commercial Officer 19,011
US:VYNE / VYNE Therapeutics Inc. Chief Commercial Officer 109,246
US:FOMX / Foamix Pharmaceuticals Ltd. Chief Commercial Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Wiley Matthew T.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BTAI / BioXcel Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BTAI / BioXcel Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BTAI / BioXcel Therapeutics, Inc. Insider Trades
Insider Sales BTAI / BioXcel Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BTAI / BioXcel Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BTAI / BioXcel Therapeutics, Inc. Insider Trades
Insider Purchases VYNE / VYNE Therapeutics Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BTAI / BioXcel Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VYNE / VYNE Therapeutics Inc. Insider Trades
Insider Sales VYNE / VYNE Therapeutics Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BTAI / BioXcel Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VYNE / VYNE Therapeutics Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Wiley Matthew T. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-10-03 2024-10-03 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
S - Sale X -6,272 19,011 -24.81 0.55 -3,450 10,456
2024-10-03 2024-09-17 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
A - Award 21,250 25,283 526.90
2024-09-17 2024-09-16 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
S - Sale X -215 4,033 -5.06 0.69 -149 2,786
2024-09-17 2024-09-15 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
M - Exercise 750 4,248 21.44
2024-06-18 2024-06-17 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
S - Sale X -244 3,498 -6.52 1.26 -308 4,417
2024-06-18 2024-06-15 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
M - Exercise 750 3,742 25.07
2024-04-08 2024-04-04 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
S - Sale X -1,008 2,992 -25.20 2.64 -2,656 7,884
2024-04-08 2024-03-15 4 BTAI BioXcel Therapeutics, Inc.
Common Stock
M - Exercise 3,000 3,000
2022-01-19 2022-01-17 4 BTAI BioXcel Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 85,000 85,000
2021-07-02 2021-06-30 4 VYNE VYNE Therapeutics Inc.
Common Stock
F - Taxes -5,151 109,246 -4.50 3.51 -18,080 383,453
2021-04-02 2021-03-31 4 VYNE VYNE Therapeutics Inc.
Common Stock
F - Taxes -2,573 114,397 -2.20 6.84 -17,599 782,475
2021-02-24 2021-02-22 4 VYNE VYNE Therapeutics Inc.
Stock Options
A - Award 64,575 64,575
2021-02-24 2021-02-22 4 VYNE VYNE Therapeutics Inc.
Common Stock
A - Award 27,675 116,970 30.99
2021-01-05 2020-12-31 4 VYNE VYNE Therapeutics Inc.
Common Stock
F - Taxes -1,541 357,181 -0.43 1.58 -2,435 564,346
2020-12-02 2020-11-30 4 VYNE VYNE Therapeutics Inc.
Common Stock
A - Award 7,838 358,722 2.23 1.44 11,326 518,353
2020-10-02 2020-09-30 4 VYNE VYNE Therapeutics Inc.
Common Stock
F - Taxes -1,541 350,884 -0.44 1.66 -2,558 582,467
2020-07-02 2020-06-30 4 MNLO Menlo Therapeutics Inc.
Common Stock
F - Taxes -1,541 352,425 -0.44 1.73 -2,666 609,695
2020-05-08 2020-05-06 4 MNLO Menlo Therapeutics Inc.
Stock Options
A - Award 150,000 150,000
2020-05-08 2020-05-06 4 MNLO Menlo Therapeutics Inc.
Common Stock
A - Award 150,000 353,967 73.54
2020-04-07 2020-04-06 4 MNLO Menlo Therapeutics Inc.
Common Stock
F - Taxes -908 203,967 -0.44 1.40 -1,271 285,554
2020-04-07 2020-04-03 4 MNLO Menlo Therapeutics Inc.
Common Stock
A - Award 91,430 204,875 80.59
2020-04-07 2020-04-03 4 MNLO Menlo Therapeutics Inc.
Common Stock
A - Award 46,394 113,445 69.19
2020-04-02 2020-03-31 4 MNLO Menlo Therapeutics Inc.
Common Stock
F - Taxes -525 67,051 -0.78 2.68 -1,407 179,697
2020-03-11 2020-03-09 4 FOMX Foamix Pharmaceuticals Ltd.
Options
D - Sale to Issuer -96,365 0 -100.00
2020-03-11 2020-03-09 4 FOMX Foamix Pharmaceuticals Ltd.
Options
D - Sale to Issuer -100,000 0 -100.00
2020-03-11 2020-03-09 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
D - Sale to Issuer -78,799 0 -100.00
2020-03-11 2020-03-09 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
D - Sale to Issuer -35,275 78,799 -30.92
2020-03-11 2020-03-09 4 MNLO Menlo Therapeutics Inc.
Stock Options
A - Award 57,086 57,086
2020-03-11 2020-03-09 4 MNLO Menlo Therapeutics Inc.
Stock Options
A - Award 59,240 59,240
2020-03-11 2020-03-09 4 MNLO Menlo Therapeutics Inc.
Common Stock
A - Award 46,680 67,576 223.39
2020-03-11 2020-03-09 4 MNLO Menlo Therapeutics Inc.
Common Stock
A - Award 20,896 20,896
2020-03-11 3 MNLO Menlo Therapeutics Inc.
No securities beneficially owned
0
2020-03-03 2020-03-02 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
A - Award 1,993 114,074 1.78 2.68 5,336 305,433
2020-02-24 2020-02-24 4 FOMX Foamix Pharmaceuticals Ltd.
Options
A - Award 96,365 96,365
2020-02-24 2020-02-24 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
A - Award 41,299 112,081 58.35
2020-01-03 2019-12-31 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
F - Taxes -2,500 70,782 -3.41 3.28 -8,200 232,165
2019-12-03 2019-11-29 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
A - Award 9,842 73,282 15.51 2.16 21,249 158,216
2019-03-06 2019-03-05 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
P - Purchase 13,440 63,440 26.88 3.76 50,534 238,534
2018-12-04 2018-12-03 4 FOMX Foamix Pharmaceuticals Ltd.
Options
A - Award 100,000 100,000
2018-12-04 2018-12-03 4 FOMX Foamix Pharmaceuticals Ltd.
Ordinary Shares
A - Award 50,000 50,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)